Nuvation Bio Inc (NYSE: NUVB) is -2.63% lower on its value in year-to-date trading and has touched a low of $1.43 and a high of $4.16 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NUVB stock was last observed hovering at around $2.67 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $2.59, the stock is -5.92% and -5.11% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.0 million and changing -3.00% at the moment leaves the stock -10.45% off its SMA200. NUVB registered 61.87% gain for a year compared to 6-month loss of -24.71%. The firm has a 50-day simple moving average (SMA 50) of $2.7244 and a 200-day simple moving average (SMA200) of $2.8992.
The stock witnessed a -3.36% gain in the last 1 month and extending the period to 3 months gives it a 14.10%, and is -8.80% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.32% over the week and 8.09% over the month.
Nuvation Bio Inc (NUVB) has around 51 employees, a market worth around $874.29M and $2.16M in sales. Profit margin for the company is -24619.84%. Distance from 52-week low is 81.12% and -37.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-105.67%).
The EPS is expected to shrink by -504.76% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Nuvation Bio Inc (NUVB) Top Institutional Holders
205.0 institutions hold shares in Nuvation Bio Inc (NUVB), with institutional investors hold 76.67% of the company’s shares. The shares outstanding are 335.25M, and float is at 229.10M with Short Float at 9.14%. Institutions hold 56.09% of the Float.
The top institutional shareholder in the company is FMR LLC with over 28.82 million shares valued at $84.16 million. The investor’s holdings represent 13.1578% of the NUVB Shares outstanding. As of 2024-06-30, the second largest holder is ECOR1 CAPITAL, LLC with 19.21 million shares valued at $56.09 million to account for 8.7696 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 16.24 million shares representing 7.4124% and valued at over $47.41 million, while OMEGA FUND MANAGEMENT, LLC holds 6.0607 of the shares totaling 13.28 million with a market value of $38.77 million.
Nuvation Bio Inc (NUVB) Insider Activity
The most recent transaction is an insider sale by Wang Junyuan Jerry, the company’s CEO, ANHEART THERAPEUTICS LTD. SEC filings show that Wang Junyuan Jerry sold 56,361 shares of the company’s common stock on Nov 11 ’24 at a price of $2.89 per share for a total of $0.16 million. Following the sale, the insider now owns 3.87 million shares.
Nuvation Bio Inc disclosed in a document filed with the SEC on Oct 08 ’24 that Mashal Robert (Director) bought a total of 100,000 shares of the company’s common stock. The trade occurred on Oct 08 ’24 and was made at $2.20 per share for $0.22 million. Following the transaction, the insider now directly holds 100000.0 shares of the NUVB stock.
Still, SEC filings show that on Jun 25 ’24, Cui Xiangmin (Director) acquired 277,895 shares at an average price of $2.97 for $0.83 million. The insider now directly holds 2,453,131 shares of Nuvation Bio Inc (NUVB).
